“PreDiabetes Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PreDiabetes Market.
The PreDiabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the PreDiabetes Pipeline Report:
Companies across the globe are diligently working toward developing novel PreDiabetes treatment therapies with a considerable amount of success over the years.
PreDiabetes companies working in the treatment market are NanoPrecision Medical, Caelus Health, Inversago Pharma Inc., Haisco Pharmaceutical Group Co., Ltd., Valbiotis, Resverlogix, Boston Therapeutics, and others, are developing therapies for the PreDiabetes treatment
Emerging PreDiabetes therapies in the different phases of clinical trials are- OKV-119, Anaerostipes rhamnosivorans, Intestinimonas, INV-202, HSK7653, Eubacterium Hallii, Totum-63, Apabetalone, BTI-320, and others are expected to have a significant impact on the PreDiabetes market in the coming years.
In November 2024, Eli Lilly and Company (NYSE: LLY) released detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), which is the longest completed study of tirzepatide to date. Weekly injections of tirzepatide (Zepbound® and Mounjaro®) at combined doses of 5 mg, 10 mg, and 15 mg significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared to a placebo, over the 176-week period. Tirzepatide also showed sustained average weight loss of 22.9% (with the 15 mg dose) throughout the three-year treatment period for the efficacy group.
PreDiabetes Overview
Pre-diabetes is a condition characterized by blood glucose levels that are higher than normal but not yet high enough to be diagnosed as type 2 diabetes. It’s considered an intermediate stage between normal glucose levels and diabetes. Individuals with pre-diabetes are at increased risk of developing type 2 diabetes, heart disease, and stroke. However, pre-diabetes can often be reversed through lifestyle changes such as weight loss, healthy eating, and increased physical activity. Regular monitoring and early intervention can help prevent or delay the onset of type 2 diabetes in individuals with pre-diabetes.
Get a Free Sample PDF Report to know more about PreDiabetes Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/prediabetes-pipeline-insight
Emerging PreDiabetes Drugs Under Different Phases of Clinical Development Include:
OKV-119: NanoPrecision Medical
Anaerostipes rhamnosivorans: Caelus Health
Intestinimonas: Caelus Health
INV-202: Inversago Pharma Inc.
HSK7653: Haisco Pharmaceutical Group Co., Ltd.
Eubacterium Hallii: Caelus Health
Totum-63: Valbiotis
PreDiabetes Route of Administration
PreDiabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
PreDiabetes Molecule Type
PreDiabetes Products have been categorized under various Molecule types, such as
Small molecule
Cell Therapy
Peptides
Polymer
Gene therapy
PreDiabetes Pipeline Therapeutics Assessment
PreDiabetes Assessment by Product Type
PreDiabetes By Stage and Product Type
PreDiabetes Assessment by Route of Administration
PreDiabetes By Stage and Route of Administration
PreDiabetes Assessment by Molecule Type
PreDiabetes by Stage and Molecule Type
DelveInsight’s PreDiabetes Report covers around 15+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further PreDiabetes product details are provided in the report. Download the PreDiabetes pipeline report to learn more about the emerging PreDiabetes therapies
Some of the key companies in the PreDiabetes Therapeutics Market include:
Key companies developing therapies for PreDiabetes are – Resverlogix Corporation, Boston Therapeutics, vTv Therapeutics, Valbiotis, BioTeSys, SynDevRx, Caelus Health, NanoPrecision Medical, and others.
PreDiabetes Pipeline Analysis:
The PreDiabetes pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of PreDiabetes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PreDiabetes Treatment.
PreDiabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
PreDiabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PreDiabetes market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about PreDiabetes drugs and therapies
PreDiabetes Pipeline Market Drivers
Increase in prevalence of prediabetes, increase in Diagnosis and Growing investments in research and development are some of the important factors that are fueling the PreDiabetes Market.
PreDiabetes Pipeline Market Barriers
However, side effects associated with Drugs, lack of Awareness among Patients and other factors are creating obstacles in the PreDiabetes Market growth.
Scope of PreDiabetes Pipeline Drug Insight
Coverage: Global
Key PreDiabetes Companies: NanoPrecision Medical, Caelus Health, Inversago Pharma Inc., Haisco Pharmaceutical Group Co., Ltd., Valbiotis, Resverlogix, Boston Therapeutics, and others
Key PreDiabetes Therapies: OKV-119, Anaerostipes rhamnosivorans, Intestinimonas, INV-202, HSK7653, Eubacterium Hallii, Totum-63, Apabetalone, BTI-320, and others
PreDiabetes Therapeutic Assessment: PreDiabetes current marketed and PreDiabetes emerging therapies
PreDiabetes Market Dynamics: PreDiabetes market drivers and PreDiabetes market barriers
Request for Sample PDF Report for PreDiabetes Pipeline Assessment and clinical trials
Table of Contents
1. PreDiabetes Report Introduction
2. PreDiabetes Executive Summary
3. PreDiabetes Overview
4. PreDiabetes- Analytical Perspective In-depth Commercial Assessment
5. PreDiabetes Pipeline Therapeutics
6. PreDiabetes Late Stage Products (Phase II/III)
7. PreDiabetes Mid Stage Products (Phase II)
8. PreDiabetes Early Stage Products (Phase I)
9. PreDiabetes Preclinical Stage Products
10. PreDiabetes Therapeutics Assessment
11. PreDiabetes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. PreDiabetes Key Companies
14. PreDiabetes Key Products
15. PreDiabetes Unmet Needs
16 . PreDiabetes Market Drivers and Barriers
17. PreDiabetes Future Perspectives and Conclusion
18. PreDiabetes Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
